Clinicogenomic analysis of EGFR-mutant lung tumors identifies Rb pathway inactivation as a hallmark of squamous transformation.
Summary
This study investigates histologic transformation to lung squamous cell carcinoma (LUSC) in EGFR-mutant lung adenocarcinoma (LUAD) patients, an underrecognized resistance mechanism. Multiomic analyses revealed that patients with transforming or adenosquamous (LUAS) phenotypes experienced shorter overall survival on first-line osimertinib. Inactivation of the retinoblastoma (Rb) pathway, particularly via CDKN2A/B deletions, was identified as a key driver of this transformation. Furthermore, MET pathway upregulation was observed, and combined EGFR and MET inhibition demonstrated efficacy in preclinical models. These findings suggest novel strategies to counteract this aggressive form of resistance.
Analysis
Clinique: This study highlights that histologic transformation to LUSC or LUAS in EGFR-mutant LUAD patients is associated with shorter overall survival on first-line osimertinib. Rb pathway alterations, particularly CDKN2A/B deletions, serve as negative prognostic biomarkers, indicating faster resistance to osimertinib. The finding that combined EGFR and MET inhibition can suppress tumor growth in preclinical models justifies early-phase clinical trials evaluating this therapeutic combination in patients exhibiting this transformation. Clinical impact could be seen in the medium term (3-5 years) if these results are confirmed. Biomol: The study employed a comprehensive multiomic approach (genomic, transcriptomic, methylation, proteomic) to characterize transforming tumors. It discovered that Rb pathway inactivation, often through CDKN2A/B deletions, is a key mechanism driving LUSC transformation. Activation of AKT and MYC pathways, combined with Rb inactivation, was validated in in vivo models. The identification of MET pathway upregulation as a therapeutic vulnerability is a major translational discovery, suggesting that MET inhibitors could be used in combination with EGFR inhibitors to target this resistance. Patient-derived xenograft (PDX) models were instrumental in validating the efficacy of this combination. Bioinfo: Single-cell RNA profiling was a crucial bioinformatic tool to decipher the complex molecular changes during histologic transformation. This approach allowed for the confirmation of observations made on clinical specimens and the identification of MET pathway upregulation at a cellular level. While the article does not detail algorithmic architecture, the use of single-cell sequencing data provided fine-grained resolution of tumor plasticity mechanisms, offering valuable insights for understanding resistance mechanisms and identifying therapeutic targets.